Foghorn Therapeutics (FHTX) Capital Expenditures (2019 - 2026)

Foghorn Therapeutics' Capital Expenditures history runs 7 years deep, the most recent figure standing at -$28000.0 for Q2 2025.

• In Q2 2025, Capital Expenditures fell 264.71% year-over-year to -$28000.0; the TTM figure through Mar 2026 stood at -$28000.0 (down 103.36% YoY), while the FY2024 annual figure was $906000.0, down 25.98% from the prior year.
• Capital Expenditures for Q2 2025 stood at -$28000.0, down from $28000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $2.0 million in Q2 2021, with the low at -$2.9 million in Q4 2021.
• The 5-year median for Capital Expenditures is $165500.0 (2021), against an average of $143611.1.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures sank 276.96% in 2022, then surged 2750.0% in 2023.
• Foghorn Therapeutics' Capital Expenditures stood at -$2.9 million in 2021, then jumped by 98.5% to -$44000.0 in 2022, then soared by 2750.0% to $1.2 million in 2023, then sank by 58.92% to $479000.0 in 2024, then slumped by 105.85% to -$28000.0 in 2025.
• Business Quant data shows FHTX's Capital Expenditures at -$28000.0 in Q2 2025, $28000.0 in Q1 2025, and $479000.0 in Q4 2024.